{"created":"2023-06-19T10:43:40.616640+00:00","id":3946,"links":{},"metadata":{"_buckets":{"deposit":"e40cba36-28e6-481b-94d0-1982fe9c4a38"},"_deposit":{"created_by":11,"id":"3946","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3946"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003946","sets":["10:37"]},"author_link":[],"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"Journal of J Gynecologic Oncology","bibliographic_titleLang":"en"}]}]},"item_6_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"米岡, 完","creatorNameLang":"ja"}]}]},"item_6_date_granted_70":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2021-03-09"}]},"item_6_degree_grantor_68":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"滋賀医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"14202","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_6_degree_name_67":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_6_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective:\nTo treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete resection cannot be achieved by IDS, debulking surgery is performed after administering additional 3 cycles of chemotherapy without postoperative chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and determined their serum cancer antigen 125 (CA125) levels to predict complete surgery. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nA retrospective chart review of all stage III and IV ovarian, fallopian tube, and peritoneal cancer patients treated with NAC in 2007-2016 was conducted. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nAbout 117 patients comprised the IDS group and 26 comprised the Add-C group. Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the IDS group. Multivariate analysis revealed that patients who developed residual disease after surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45-3.28) and OS (HR=2.33; 95% CI=1.43-3.79), and those who received <6 cycles of chemotherapy had worse PFS (HR=5.30; 95% CI=2.56-10.99) and OS (HR=3.05; 95% CI=1.46-6.38). The preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions:\nAdministering 3 additional cycles of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of achieving complete surgery. ","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_6_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Thesis or Dissertation","subitem_description_type":"Other"}]},"item_6_description_69":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"令和2年度","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_6_dissertation_number_71":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第455号"}]},"item_6_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Asian Society of Gynecologic Oncology","subitem_publisher_language":"en"}]},"item_6_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"31328461","subitem_relation_type_select":"PMID"}}]},"item_6_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.3802/jgo.2019.30.e81"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3802/jgo.2019.30.e81","subitem_relation_type_select":"DOI"}}]},"item_6_relation_48":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"博士論文要旨"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://hdl.handle.net/10422/00013005","subitem_relation_type_select":"HDL"}}]},"item_6_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology. "}]},"item_6_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2005-0399 ","subitem_source_identifier_type":"EISSN"}]},"item_6_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"YONEOKA, Yutaka","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-14"}],"displaytype":"detail","filename":"jgo.2019.30.e81.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensefree":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"jgo.2019.30.e81","objectType":"fulltext","url":"https://shiga-med.repo.nii.ac.jp/record/3946/files/jgo.2019.30.e81.pdf"},"version_id":"7b42116f-e490-4f2c-949f-c4ed3c012157"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"CA-125 Antigen","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cytoreduction Surgical Procedures","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Neoadjuvant Therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ovarian Neoplasm","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?","subitem_title_language":"en"}]},"item_type_id":"6","owner":"11","path":["37"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-07-14"},"publish_date":"2021-07-14","publish_status":"0","recid":"3946","relation_version_is_last":true,"title":["Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-09-15T05:18:31.239357+00:00"}